What is Elektrofi?
Elektrofi, Inc. is a specialized biotechnology firm dedicated to the transformation of biologic medicine delivery. By leveraging expertise in fluid mechanics, microsystems engineering, and protein formulation, the company has developed innovative technologies that facilitate the subcutaneous administration of biologics. This approach effectively replaces the need for conventional, time-intensive intravenous infusions, thereby enhancing patient convenience and treatment accessibility.
The organization operates at the intersection of pharmaceutical science and advanced engineering. Its core mission is to redefine the delivery of complex biologic therapies, providing healthcare systems with more flexible and efficient treatment options. As a pioneer in this niche, Elektrofi continues to bridge the gap between laboratory-based innovation and clinical application, addressing critical bottlenecks in the current biopharmaceutical supply chain.
How much funding has Elektrofi raised?
Elektrofi has raised a total of $152.7M across 4 funding rounds:
Debt
$150K
Debt
$332K
Series B
$40M
Series C
$112.3M
Debt (2020): $150K with participation from PPP
Debt (2021): $332K led by PPP
Series B (2022): $40M supported by Janus Henderson, Marshall Wace, BVF Partners, and Logos Capital
Series C (2024): $112.3M featuring RA Capital Management, Novo Holdings, and Royalty Pharma
Key Investors in Elektrofi
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its internal TechAtlas think tank to guide strategic decisions.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, serving as a major investor in life science innovation.
Royalty Pharma
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation, collaborating with academic institutions and global pharmaceutical companies to support late-stage clinical development.
What's next for Elektrofi?
With the successful completion of its latest financing round, Elektrofi is poised to scale its operations and deepen its pipeline of formulation technologies. The capital will likely be deployed to support late-stage clinical trials and the commercialization of its delivery platforms. As the company transitions into this next phase of growth, the focus will remain on strategic partnerships with global pharmaceutical entities to integrate its technology into existing and future biologic portfolios.
The backing from major life science investors suggests a clear path toward market leadership. Elektrofi's ability to secure substantial resources indicates that its technology is viewed as a critical component in the future of patient-centric care, potentially setting a new standard for how biologic medicines are administered worldwide.
